Dissecting mechanisms of immunotherapy-induced plasticity in AML through multi-omics and genome-wide CRISPR screens (B04)

• Subject Area: Hematology, Oncology
• Term: since 2025
• Project identifier: Deutsche Forschungsgemeinschaft (DFG) - Project number 533056198

Project B04 will characterize the impact of the inflammatory AML environment and identify mechanisms of AML plasticity in response to therapeutic pressure mediated by CAR T cells targeting CD33 and CD70, and ADCs such as gemtuzumab ozogamicin. B04 will utilize single-cell multiomics analyses and genome-wide CRISPR knockout and overexpression screens to uncover the mechanisms that hinder the effectiveness of immunotherapy in AML, enabling the development of novel and innovate treatment strategies that will overcome these limitations.

• DFG Programme: Collaborative Research Centres
• Subproject of: SFB 1709: Cellular Plasticity in Myeloid Malignancies: From Mechanisms to Therapies
• Applicant Institution: Ruprecht-Karls-Universität Heidelberg
• Project Heads: Dr. Franziska Blaeschke; Dr. Tim Sauer